title: [A clinico-pathological and immunohistochemical study on anaplastic large cell lymphoma].
abstract: OBJECTIVE
  To study the clinicopathological characteristics, immunophenotype and biologic behavior of anaplastic large cell lymphoma (ALCL).
  
  
  METHODS
  Clinicopathological and immunohistochemical methods (ABC method) were used to analyse 8 cases of ALCL and followed for 6 to 25 months.
  
  
  RESULTS
  Eight ALCL patients (4 male and 4 female) accounted for 4.1% of the 195 lymphomas seen from 1994 to 1997. Average age was 40 years. Two tumors were located in the skin, the remainder were systemic. Clinical stage: stage I, 2 cases; stage II, 1 case; stage III, 5 cases. Histopathology: Tumor cells exhibited high pleomorphism and a large amount of mitotic figures. Reactive components (cells) often observed in the background. Immunohistochemical studies found that all tumors reacted positively with CD30 and negatively with CD15. Five cases expressed T-cell's markers (CD3, UCHL-1, CD43) and three expressed B-cell markers (CD79a, L26). After chemotherapy, two patients with cutaneous type ALCL had complete remission and survived 14 and 25 months respectively. Of the six systemic cases, three survived for 6-8 months, the remaining three died at 2 days, 20 days and 18 months after diagnosis.
  
  
  CONCLUSIONS
  This study found that ALCL was a group of lymphomas showing similarity in morphology but diversity in clinical presentation and immunophenotype. Even if the tumor is very responsive to chemotherapy, ALCL remains a high grade malignant lymphoma.
authors.affiliation: Department of Pathology, Ruijin Hospital, Shanghai Second Medical University, Shanghai 200025.
authors.forename: X
authors.initials: X
authors.lastname: Jin
authors.forename: C
authors.initials: C
authors.lastname: Li
authors.forename: C
authors.initials: C
authors.lastname: Ding
authors.forename: Q
authors.initials: Q
authors.lastname: Chu
mesh_terms: D000293:Adolescent; D015703:Antigens, CD / Q000032:analysis; D017252:CD3 Complex / Q000032:analysis; D051925:CD79 Antigens; D002648:Child; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D017730:Ki-1 Antigen / Q000032:analysis; D017493:Leukocyte Common Antigens / Q000032:analysis; D051917:Leukosialin; D017728:Lymphoma, Large-Cell, Anaplastic / Q000276:immunology / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011947:Receptors, Antigen, B-Cell / Q000032:analysis; D012795:Sialoglycoproteins / Q000032:analysis; D016019:Survival Analysis
chemical_list: D015703:Antigens, CD; D017252:CD3 Complex; D051925:CD79 Antigens; C497881:CD79A protein, human; D017730:Ki-1 Antigen; D051917:Leukosialin; D011947:Receptors, Antigen, B-Cell; C465014:SPN protein, human; D012795:Sialoglycoproteins; D017493:Leukocyte Common Antigens